Vera Therapeutics, Inc.
VERA
$28.82
-$0.48-1.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.35% | 29.55% | 14.19% | 8.32% | 8.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.87% | 33.82% | 4.63% | -3.11% | 12.22% |
| Operating Income | -63.87% | -33.82% | -4.63% | 3.11% | -12.22% |
| Income Before Tax | -58.50% | -30.75% | -0.47% | 7.58% | -7.79% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -58.50% | -30.75% | -0.47% | 7.58% | -7.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.50% | -30.75% | -0.47% | 7.58% | -7.79% |
| EBIT | -63.87% | -33.82% | -4.63% | 3.11% | -12.22% |
| EBITDA | -91.50% | -46.79% | -5.53% | 4.82% | 22.65% |
| EPS Basic | -19.86% | 9.65% | 33.85% | 40.34% | 31.42% |
| Normalized Basic EPS | -19.89% | 9.55% | 33.65% | 40.02% | 30.79% |
| EPS Diluted | -19.86% | 9.65% | 33.85% | 40.34% | 31.42% |
| Normalized Diluted EPS | -19.89% | 9.55% | 33.65% | 40.02% | 30.79% |
| Average Basic Shares Outstanding | 29.60% | 33.13% | 42.11% | 53.78% | 60.71% |
| Average Diluted Shares Outstanding | 29.60% | 33.13% | 42.11% | 53.78% | 60.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
